Key Highlights:
- HAB Pharmaceuticals and Signature Phytochemical Industries have completed a strategic merger through a slump sale, consolidating both businesses into a single entity with an estimated combined turnover of nearly ₹600Cr after intercompany sales. Finalized in March 2026, the merger aims to streamline operations, unify corporate systems, and strengthen governance while supporting long-term growth and operational efficiency
- The merged entity is expanding its manufacturing and R&D capabilities with a focus on specialty therapies, including oncology, autoimmune disorders, chronic diseases, and rare conditions. The company is also targeting growth across Latin America, Central Asia, Southeast Asia, and Africa, building on regulatory audits already completed in Uganda, Tanzania, and Iraq
- HAB Pharma is commissioning two new manufacturing facilities expected to begin commercial production by Aug 2026, including a sterile plant for semaglutide, prefilled syringes, injectables, vials, and lyophilized products, alongside a fully automated closed-loop oral solid dosage plant. The company plans to scale revenues to ₹2,500–3,000Cr by 2030 through expanded manufacturing capacity, complex dosage forms, off-patent molecules, and strengthened global commercialization efforts
Implications:
The merger gives HAB Pharma a bigger scale story: a cleaner corporate structure, more manufacturing capacity, and a stronger platform to sell specialty products in more markets. The key market implication is that it is moving from a mid-sized API/finished-dose player toward a more integrated specialty pharma company with better export potential.
The new sterile and oral-solid plants, especially the semaglutide and injectable capabilities, could help HAB win more complex manufacturing business and support future launches in oncology, autoimmune, chronic, and rare diseases. If it executes well, the merger should improve margins, speed up international expansion, and support its ₹2,500–3,000Cr revenue target by 2030.
Source: Express Pharma
No Comment! Be the first one.